TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29985860
Drug: Telenursing intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telenursing intervention with weekly follow-up phone calls for 12 weeks and availability of telenurse for calls anytime.
Study: 26818893
Drug: Insulin initiation
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin initiation willingness
Study: 26818893
Drug: Socioeconomic status
Normalized name: Statuss Green Reformulated Jan 2012
Approvals — FDA: no, EMA: no, PMDA: no
Description: Socioeconomic status and insulin appraisals
Study: 26983672
Drug: Passive physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passive physical therapy (Arm B)
Study: 19190878
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIG) 1g/kg for two consecutive days (total dose 2 g/kg)
Study: 19190878
Drug: Intravenous anti-D
Normalized name: anti-D (rh) immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous anti-D immunoglobulin 75 microg/kg (single dose)
Study: 16187243
Drug: Pamidronate (treatment)
DrugBank: Pamidronic acid (DB00282)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pamidronate (treatment)
Study: 9581302
Drug: Cefixime (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefixime (8 mg/kg per day for 5 days)
Study: 8229498
Drug: Trimethoprim-sulfamethoxazole (TMP-SMX,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole (TMP-SMX, 10-50 mg/kg per day for 5 days)
Study: 31199595
Drug: Reconval K1
Normalized name: vitamin K1
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reconval K1 cream
Study: 26994228
Drug: GDHT (goal-directed
Approvals — FDA: no, EMA: no, PMDA: no
Description: GDHT (goal-directed haemodynamic treatment)
Study: 26994228
Drug: Routine fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine fluid treatment (clinician-guided)
Study: 24217219
Drug: Cortisol infusion
Normalized name: cortisol succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol infusion to increase plasma cortisol concentration to a level associated with major physiologic stress.
Study: 24217219
Drug: Saline pre-treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline pre-treatment (Control group).
Study: 19567826
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch (21 mg/24 hr)
Study: 12359986
Drug: Dietary intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary intervention program administered by a dietitian
Study: 12359986
Drug: Dietary intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary intervention program administered by a doctor of chiropractic in conjunction with chiropractic spinal manipulation
Study: 28784536
Drug: Matcha tea
Normalized name: Matcha Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matcha tea bar (4 g matcha tea powder)
Study: 21494061
Drug: Wisdom psychotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wisdom psychotherapy (PTED-specific cognitive behaviour therapy)
Study: 21494061
Drug: Routine multidimensional
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine multidimensional cognitive behaviour therapy
Study: 16794200
Drug: Dispersible aspirin
Normalized name: Disperse Blue 106
DrugBank: Disperse Blue 106 (DB14203)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dispersible aspirin 75 mg
Study: 16794200
Drug: Enteric-coated 75
Normalized name: EC-0652
DrugBank: EC-0652 (DB15340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated 75 mg aspirin
Study: 16794200
Drug: Asasantin (25-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asasantin (25-mg standard release aspirin plus 200-mg modified-release dipyridamole given twice daily)
Study: 16794200
Drug: Other aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Other aspirin preparations (3 different enteric-coated 75 mg aspirins)
Study: 3295148
Drug: Computer-assisted dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-assisted dosing (Warfcalc)
Study: 30872375
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg THC
Study: 11502903
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 300 mg twice daily
Study: 11502903
Drug: Remacemide hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Remacemide (DB06458)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remacemide hydrochloride 200 mg three times daily
Study: 11502903
Drug: Placebo (neither
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (neither treatment)
Study: 7963729
Drug: HIV subunit
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV subunit vaccine (rgp120SF2) combined with MF59 adjuvant
Study: 1316584
Drug: Felodipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine (10 mg)
Study: 25075
Drug: Timolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol (10 mg)
Study: 2442512
Drug: Timolol and
Normalized name: timolol and thiazides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol and all beta-blocker/felodipine combinations
Study: 2442512
Drug: Felodipine/beta-blocker combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine/beta-blocker combinations
Study: 28167477
Drug: Entoban capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entoban capsule 400mg every 8 hours for five days
Study: 28167477
Drug: Metronidazole tablets
Normalized name: Metronidazole Tablets
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole tablets (400 mg) for 7‐10 days
Study: 25758273
Drug: Rosuvastatin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin treatment
Study: 23547489
Drug: Tongue cleaning
Normalized name: beef tongue preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tongue cleaning with meridol HALITOSIS tooth & tongue gel (C)
Study: 23547489
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (A)
Study: 23379974
Drug: Fidaxomicin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fidaxomicin (200 mg twice daily for 10 days)
Study: 19463375
Drug: CYP2C19*1*1 carriers
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYP2C19*1*1 carriers after a 600-mg dose
Study: 19463375
Drug: CYP2C19*2 or
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYP2C19*2 or *4 carriers after a 600-mg dose
Study: 19463375
Drug: CYP2C19*17 carriers
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYP2C19*17 carriers after a 600-mg dose
Study: 19463375
Drug: CYP2C19*2 or
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYP2C19*2 or *4 carriers with higher loading dose at 4 h
Study: 19463375
Drug: CYP2C19*2 or
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYP2C19*2 or *4 carriers with higher maintenance dose regimen
Study: 14749149
Drug: BIAsp 30
Normalized name: Fiasp
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: BIAsp 30 + ROS (biphasic insulin aspart 30 plus rosiglitazone 4 mg once daily)
Study: 14749149
Drug: GLIB +
Normalized name: glibornuride
DrugBank: Glibornuride (DB08962)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLIB + ROS (glibenclamide plus rosiglitazone 4 mg once daily)
Study: 10826396
Drug: Doxazosin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin (1 to 16 mg/day)
Study: 8858401
Drug: L-carnitine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (3 g/day for 3 weeks)
Study: 8858401
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 g/day for 3 weeks)
Study: 24995700
Drug: Selective iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective iron group (elemental iron 50 mg twice a day if diagnosed as anaemic)
Study: 24995700
Drug: Routine iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine iron group (elemental iron 100 mg day(‐1) throughout pregnancy)
Study: 22762951
Drug: Peer change
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peer change agent (PCA) identification and recruitment methodology based on social network analysis.
Study: 17919489
Drug: HCV-specific CD8
Normalized name: HCV-086
DrugBank: HCV-086 (DB05884)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCV-specific CD8 T-cell response before treatment
Study: 17919489
Drug: HCV-specific CD8
Normalized name: HCV-086
DrugBank: HCV-086 (DB05884)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCV-specific CD8 T-cell responses during the first weeks of therapy
Study: 17919489
Drug: Late treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late treatment phase T-cell responses
Study: 11570617
Drug: Zafirlukast, 20
Normalized name: Zafirlukast, 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zafirlukast, 20 mg twice daily
Study: 9924306
Drug: Prophylactic laser
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic laser treatment (argon green laser, approximately 100 mild laser burns)
Study: 31585796
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 500 mL of crystalloid solution
Study: 28095397
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment utility (OTU)
Study: 25769361
Drug: Higher-dose edoxaban
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-dose edoxaban (60 mg once daily)
Study: 25769361
Drug: Lower-dose edoxaban
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower-dose edoxaban (30 mg once daily)
Study: 25769361
Drug: Warfarin (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (dose adjusted to INR 2.0-3.0)
Study: 19996654
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral EMP 10 mg/kg in 3 doses
Study: 19996654
Drug: Low-dose EMP
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose EMP 3 mg/kg once daily plus VP16 25 mg/m(2) once daily on days 1 through 14
Study: 16335163
Drug: Immediately loaded
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediately loaded TiUnite implants
Study: 16335163
Drug: Brånemark implants
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brånemark implants (control)
Study: 12077735
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy plus 1 mg hydroxocobalamin administered subcutaneously once per week after dialysis
Study: 12077735
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (5 to 6 mg folic acid, 5 to 10 mg pyridoxine, and 6 to 10 microg oral vitamin B(12) per day)
Study: 9860110
Drug: Morphine 40
Normalized name: morphine 40 mg/12 to 24 hr oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 40 mg
Study: 219964
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (13 courses of three infusions over 3 years, each infusion containing 12 mg/kg cyclophosphamide, 12 mg/kg 5‐fluorouracil, 0.5 mg/kg methotrexate, 0.1 mg/kg vinblastine)
Study: 30336181
Drug: Adalimumab in
Normalized name: adalimumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab in combination with methotrexate (20 or 40 mg, according to body weight)
Study: 30336181
Drug: Methotrexate alone
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate alone (up to 25 mg weekly)
Study: 17143593
Drug: Pectoral stretching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pectoral stretching program (daily low-load, prolonged stretches)
Study: 14730599
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with DMARDs (sulfasalazine, methotrexate, hydroxychloroquine) plus prednisolone
Study: 14730599
Drug: Single therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single therapy with a DMARD with or without prednisolone
Study: 12575592
Drug: Antibiotics plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics plus Chinese drugs combined treatment
Study: 12575592
Drug: Simple antibiotics
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple antibiotics treatment
Study: 9456641
Drug: 0.12% chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12% chlorhexidine digluconate (Peridex) mouthrinses, twice daily for 6 days per week, supervised for 3 months
Study: 9456641
Drug: Placebo mouthrinses,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo mouthrinses, twice daily for 6 days per week, supervised for 3 months
Study: 29396738
Drug: Genetic-guided warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genetic-guided warfarin arm (GEN)
Study: 26603056
Drug: Nintedanib 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nintedanib 200 mg twice daily plus Best Supportive Care (BSC)
Study: 7584746
Drug: Nebulized albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized albuterol (ALB) 2.5 mg
Study: 7584746
Drug: Subcutaneous terbutaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous terbutaline (TERB) 0.25 mg
Study: 6932207
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg PG F2α
Study: 6932207
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg PG F2α
Study: 6932207
Drug: Combined prostaglandin-treated
Normalized name: trimethylsilyl treated diimethiconol-trimethylsiloxysilicate crosspolymer (45-55 WW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined prostaglandin-treated group (25 mg and 50 mg PG F2α)
Study: 27568072
Drug: Calcium and
Normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium and vitamin D supplementation (800mg calcium and 400IU vitamin D daily, n=8)
Study: 26525550
Drug: Fast-track surgery
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast-track surgery combined with Chinese medicine treatment
Study: 23351578
Drug: Wax-matrix extended-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wax-matrix extended-release niacin (WMER) 1500 mg/d
Study: 23351578
Drug: Inositol hexanicotinate
Normalized name: Inositol hexanicotinate
DrugBank: Inositol nicotinate (DB08949)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inositol hexanicotinate (IHN) 1500 mg/d
Study: 18801639
Drug: Self-help treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-help treatment (book and 6 weeks of DVD or videotape)
Study: 11403176
Drug: Pilocarpine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilocarpine (5 mg three times per day starting the day before radiation therapy)
Study: 8933126
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g of raw ginger root daily for two weeks
Study: 8933126
Drug: 40 g
Normalized name: PEG-40 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g of cooked stem ginger daily for two weeks
Study: 4064546
Drug: 50.0 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50.0 Gy in 20 daily fractions
Study: 4064546
Drug: 52.5 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 52.5 Gy in 20 daily fractions
Study: 4064546
Drug: 57.5 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 57.5 Gy in 20 daily fractions
Study: 30032505
Drug: 200 ml
Normalized name: Bag Top-Fill, 1200 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 ml 12.5% CHO
Study: 30032505
Drug: 300 ml
Normalized name: HYQVIA 30 GM / 300 ML Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 ml 12.5% CHO
Study: 30032505
Drug: 400 ml
Normalized name: Lantidra 400 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 ml 12.5% CHO
Study: 30032505
Drug: 500 ml
Normalized name: TPN Bag 500 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ml 12.5% CHO
Study: 24332514
Drug: Oral ibandronic
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ibandronic acid 50 mg daily
Study: 24332514
Drug: Intravenous zoledronic
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous zoledronic acid 4 mg every 3-4 weeks
Study: 20690416
Drug: Maxcem (MA)
Normalized name: Mielim Y Mas
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maxcem (MA) with tribochemical treatment
Study: 20690416
Drug: Smartcem (SM)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Smartcem (SM) with tribochemical treatment
Study: 20690416
Drug: Rely X
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rely X Unicem Aplicap (UN) with tribochemical treatment
Study: 20690416
Drug: Breeze (BR)
Normalized name: Halls Breezers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breeze (BR) with tribochemical treatment
Study: 20690416
Drug: Biscem (BI)
Normalized name: bis-ethoxydiglycol succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biscem (BI) with tribochemical treatment
Study: 20690416
Drug: Set (SE)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Set (SE) with tribochemical treatment
Study: 20690416
Drug: Clearfil SA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clearfil SA luting (CL) with tribochemical treatment
Study: 16182353
Drug: d-Amphetamine (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-Amphetamine (0, 2.5, 5, 10 and 15 mg) alone
Study: 16182353
Drug: Oxazepam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxazepam (20 mg) + d-Amphetamine (15 mg)
Study: 2278365
Drug: Etomidate in
Normalized name: etomidate Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate in lipid emulsion (20 mg in 10 ml of Lipofundin MCT 20%)
Study: 2278365
Drug: Etomidate in
Normalized name: etomidate Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate in propylene glycol (35% solution)
Study: 20170026
Drug: Initiation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initiation of therapy for ovarian cancer
Study: 17710561
Drug: Pharmacist recommendations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist recommendations for drug therapy changes (267 recommendations total)
Study: 17710561
Drug: Pharmacist recommendations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist recommendations to add a new antihypertensive medication (46.4%) or increase a dose (33.3%)
Study: 17710561
Drug: Pharmacist recommendations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist recommendations for no change in treatment plan (361 times)
Study: 9591815
Drug: Tazarotene 0.05%
Normalized name: TAZAROTENE 0.05% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tazarotene 0.05% gel
Study: 1997933
Drug: Metoclopramide (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (3 mg/kg, 15 min i.v.)
Study: 1997933
Drug: Droperidol (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol (1.25 mg slow push)
Study: 30898462
Drug: Physician choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician choice of antibiotic
Study: 25085298
Drug: Carbon dioxide
Normalized name: Carbon Dioxide
DrugBank: Carbon dioxide (DB09157)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbon dioxide laser treatment (beam diameter, 0.2 mm; power, 0.7 W)
Study: 22147075
Drug: Dacomitinib (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dacomitinib (45 mg) plus Dextromethorphan (DM)
Study: 17382026
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus EGFR tyrosine kinase inhibitors (gefitinib or erlotinib)
Study: 15105062
Drug: Triphasic combined
Normalized name: Tribasic Calcium Phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triphasic combined oral contraceptive (COC)
Study: 12192203
Drug: Potential future
Normalized name: Potentilla discolor whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potential future therapies and prophylactic recommendations
Study: 8130022
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (Bendrofluazide + Loop diuretic)
Study: 8130022
Drug: Prolonged treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged treatment (Bendrofluazide + Loop diuretic)
Study: 8130022
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (Bendrofluazide + Metolazone + Loop diuretic)
Study: 23303874
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (15 mg daily)
Study: 29973165
Drug: Individual Health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual Health Management (IHM) lifestyle program, including access to a web-based health portal and participation in training sessions (3 full-day and 10 two-hour sessions in the first 3 months, followed by 4 training sessions and weekly monitoring for 9 months).
Study: 26630910
Drug: High-intensity functional
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity functional exercise program (intensive strengthening and balance exercises in small groups twice a week for 12 weeks)
Study: 24517948
Drug: Continuous-infusion elastomeric
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous-infusion elastomeric pump with local anesthetic (LA)
Study: 16231250
Drug: Dalbavancin (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalbavancin (1000 mg IV on day 1 and 500 mg IV on day 8)
Study: 16231250
Drug: Linezolid (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linezolid (600 mg IV or orally every 12 hours for 14 days)
Study: 12470424
Drug: Hepatic arterial
Normalized name: Sus scrofa artery preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatic arterial infusion (HAI) of activated leukocytes after stimulation with GM-CSF
Study: 12470424
Drug: Hepatic arterial
Normalized name: Sus scrofa artery preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatic arterial infusion (HAI) of activated leukocytes after stimulation with IL-2